Valuation : EnteroMedics Inc

Market Cap 14.46M 12.47M 11.8M 10.7M 20.05M 1.38B 20.17M 140M 53.83M 702M 54.3M 53.1M 2.22B P/E 2026 *
-3.61x
P/E 2027 * -2.58x
Enterprise Value 14.46M 12.47M 11.8M 10.7M 20.05M 1.38B 20.17M 140M 53.83M 702M 54.3M 53.1M 2.22B EV / Sales 2026 *
108x
EV / Sales 2027 * 72.3x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 133K 115K 109K 98.63K 185K 12.74M 186K 1.29M 496K 6.47M 501K 490K 20.47M 200K 172K 163K 148K 277K 19.11M 279K 1.94M 745K 9.71M 751K 735K 30.71M
Net income -4M -3.45M -3.26M -2.96M -5.55M -382M -5.58M -38.74M -14.89M -194M -15.02M -14.69M -614M -7.85M -6.77M -6.4M -5.8M -10.88M -750M -10.95M -75.98M -29.21M -381M -29.47M -28.82M -1.2B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!